Evidence map›Paper›PMID 39744525›Full record

ArticleFrontiers in medicine2024

Sanja Matic, Dragan Milovanovic, Zeljko Mijailovic, Predrag Djurdjevic, Srdjan Stefanovic, Danijela Todorovic, Katarina Vitosevic, Vanja Canovic, Suzana Popovic, Nevena Milivojevic Dimitrijevic and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sanja MaticDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Dragan MilovanovicDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Zeljko MijailovicDepartment of Infectious Diseases, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Predrag DjurdjevicDepartment of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Srdjan StefanovicDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Danijela TodorovicDepartment of Genetics, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Katarina VitosevicDepartment of Forensic Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Vanja CanovicDepartment of Forensic Medicine and Toxicology, University Clinical Center Kragujevac, Kragujevac, Serbia.
Suzana PopovicCentre for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Nevena Milivojevic DimitrijevicBioengineering Research and Development Center (BioIRC), Kragujevac, Serbia.
Marko ZivanovicBioengineering Research and Development Center (BioIRC), Kragujevac, Serbia.
Dragana SeklicDepartment of Sciences Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia.
Sanja AleksicClinic for Haematology, University Clinical Centre Kragujevac, Kragujevac, Serbia.
Nemanja DjordjevicDepartment of Infectious Diseases, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Milena VukicDepartment of Chemistry, Faculty of Sciences, University of Kragujevac, Kragujevac, Serbia.
Nenad VukovicDepartment of Chemistry, Faculty of Sciences, University of Kragujevac, Kragujevac, Serbia.
Nenad FilipovicBioengineering Research and Development Center (BioIRC), Kragujevac, Serbia.
Dejan BaskicCentre for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Natasa DjordjevicDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: ACE2 and TMPRSS2 represent the major gateways for SARS-CoV-2 cell entry. The presence of functional ACE2 and TMPRSS2 genetic polymorphisms that affect gene expression may affect the risk of severe form of COVID-19 and its fatal outcome. Material and patients: This observational study enrolled 178 hospitalized patients diagnosed with SARS-CoV-2 infection at the University Clinical Centre of Kragujevac, Serbia. Demographic, clinical, and laboratory data were gathered at admission. Genotyping for single nucleotide polymorphisms of Results: Controlling for other factors of influence, such as CCI, N/L ratio, LDH level, and pO Conclusion: Our findings indicate

Indexed as

ACE2COVID-19outcomeseverityTMPRSS2

Identifiers

PMID39744525
PMCPMC11688283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.